Volume Alert - MRK 59.33 Merck & Company $MRK Hit a high

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - MRK 59.33 Merck & Company $MRK Hit a high today of 59.69 Closing the day 10:30 at 59.33 -0.56 -0.94% With a day low of 59.13 and a total volume of 1,391,209.

MRK Recent Posts: http://investorshangout.com/Merck--Company-MRK-51867/

MRK Merck & Company Recent Headline News

Global Single Use Bioreactor Market Outlook, 2019: Thermo Fischer Scientific, Sartorius, Merck, GE Healthcare & Pall Corp Dominate the $200+ Million Market
M2 - 1 hr 6 mins ago
Research and Markets (http://www.researchandmarkets.com/research/k5b5rm/single_use) has announced the addition of the "Single Use Bioreactor Market by Product Type, Cell Type, Technology, End User - Global Forecast to 2019" report to their offering. The single use bioreactors (SUBs) market is expected to grow at a double digit CAGR of 18.4% to reach $470.9 million by 2019 from $202.5 million in 2014 Major factors fueling the growth of this market are low requirements of capital investment for setting up the facility, reduced complexity of automation, and energy efficiency. However, regulatory concerns regarding the mixing process, contamination by leachables and extractable, and difficulties in meeting good manufacturing practices (GMP) standards are restricting the growth of the single use bioreactor market. The single use bioreactor market is segmented on the basis of molecule type (monoclonal antibodies (MAbs), vaccines, gene therapy, recombinant proteins, stem cells, and others (growth factors, interferons, antisense, RNA interference)), type of cell (mammalian cell, bacterial cell, yeast cell and others (insect cell and plant cell)), technology (wave-induced motion SUBs, stirred SUBs, single-use bubble column bioreactors, and others (single-use reactors with vertically perforated discs and single-use hybrid reactors)), end users (R&D (CROs, biopharmaceutical manufacturers, and research institutes) and biopharmaceutical manufacturers), and region (North America, Europe, Asia-Pacific, RoW). MAbs is the largest segment of the single use bioreactor market by molecule type. The high growth rate of this segment can be attributed to the growing demand for SUBs in small-scale manufacturing of MAbs as a result of low investment costs, low requirement of manpower, reduction in time-consuming changeover procedures. The mammalian cells segment of the market by type of cell is the largest and fastest-growing segment, owing to successful employment of SUB for mammalian cell cultures for clinical and commercial drug manufacturing. The R&D department of CROs, biopharmaceutical manufacturers, and research institutes is the major end-user segment of the single use bioreactor market. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Insights 7 Single Use Bioreactor Market, By Technology 8 Single Use Bioreactor Market, By Molecule Type 9 Single Use Bioreactor Market, By Type Of Cell 10 Single Use Bioreactor Market, By End User 11 Single Use Bioreactor Market, By Geography 12 Competitive Landscape 13 Company Profiles - Applikon Biotechnology - Cellexus Limited - Cellution Biotech - GE Healthcare (Subsidiary Of General Electric Company) - Merck Kgaa - Pall Corporation - Parker Hannifin Corporation - Pbs Biotech, Inc. - Sartorius Ag - Thermo Fisher Scientific, Inc. For more information visit http://www.researchandmarkets.com/research/k5b5rm/single_use
GE: 26.82 (-0.19), PLL: 94.60 (-0.02), MRK: 59.51 (-0.38)

Ezetimibe/simvastatin used in a fixed-dose combination Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
CNW Group - 2 hrs 35 mins ago
Merck, known as MSD outside of Canada and the United States, announced on November 17, 2014, that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine ezetimibe/simvastatin in a fixed-dose combination - the fixed-dose combination of ezetimibe/simvastatin is not available in Canada; the individual components: simvastatin (ZOCOR®) and ezetimibe (EZETROL®) are available in Canada - experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented on November 17 during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.51 (-0.38)

Global Human Microbiome Market Report: Disease, Application & Product Analysis 2014-2019 & 2023
M2 - Wed Nov 19, 5:09AM CST
Research and Markets (http://www.researchandmarkets.com/research/sc2wtl/human_microbiome) has announced the addition of the "Human Microbiome Market by Disease, Application & by Product - Global Forecast to 2023" report to their offering. The human microbiome market is expected to be valued as $294 million in 2019 and is poised to grow at a CAGR of 22.3% within the forecast period of 2019-2023 Moreover, rising incidences of cardiac diseases and other diseases such as diabetes and obesity are also expected to contribute to the growth of the human microbiome market. Increasing side effects and diminishing of human gut flora, due to excessive use of antibiotics, is likely to drive the growth of the human microbiome market. The application market is also expected to be a prominent segment owing to the use of microbiome as diagnostics and therapeutics. The evidence from intransigent research resulted the use of microbiomes as biomarkers and diagnosis of various diseases. The disease segment, on the other hand, will be the fastest-growing segment in the coming years. With the growing incidences and increasing awareness of lifestyle diseases this market is set to grow at a fast pace. The grey area while estimating the market size was the uncertainty factor that lies with the current regulatory scenario for various products. The insights were provided by the industry experts who later clarified as to which disease segment will witness product approvals by the regulatory authorities and will enter the market in the future. Scope of the Report - Disease (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) - Application (Therapeutic, Diagnostic) - Product (Probiotic, Prebiotic, Food, Medical Food, Supplement, Device, Drug) Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Industry Trends 7 Human Microbiome Market, By Disease 8 Human Microbiome Market, By Application 9 Market, By Product 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - E. I. Du Pont De Nemours And Company - Enterome Bioscience - Merck & Co., Inc. - Metabiomics Corporation - Microbiome Therapeutics Llc. - Osel Inc. - Second Genome, Inc. - Vedanta Biosciences - Vithera Pharmaceuticals - Yakult Honsha Co., Ltd. For more information visit http://www.researchandmarkets.com/research/sc...microbiome
MRK: 59.51 (-0.38)

Gilead's Value Without Its Hep C Franchise
Tim Harrison - at Seeking Alpha - Tue Nov 18, 3:07PM CST

JNJ: 108.29 (-0.54), GILD: 102.17 (-1.54), MRK: 59.51 (-0.38), AMGN: 162.78 (+0.54), ABBV: 65.57 (-0.48), BMY: 58.57 (-0.13), CELG: 107.43 (+0.65)

Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 18, 3:00PM CST
Pop quiz: Which one of these drug companies released major positive clinical trial data yesterday? Company Intraday Increase Monday from Friday's Close Merck 1.4% Regeneron Pharmaceuticals 3.3% ...
ESPR: 31.91 (-0.61), MRK: 59.51 (-0.38), REGN: 416.85 (+3.63)

Product and Pipeline Analysis of the Global Vaccines Market : Expected Launches in the Areas of Cancer and Allergies Will Drive Growth
PR Newswire - Tue Nov 18, 11:03AM CST
Executive Summary
MRK: 59.51 (-0.38), GSK: 46.37 (+0.09), NVS: 95.70 (+0.12)

Sanofi: Recent Plunge Is A Buying Opportunity
Nicholas Kitonyi - at Seeking Alpha - Tue Nov 18, 8:00AM CST

NVO: 44.74 (+0.52), PFE: 30.35 (-0.24), MRK: 59.51 (-0.38), LLY: 67.11 (-0.67), SNY: 48.31 (-0.05), MNKD: 6.55 (-0.05)

Merck Updates on Anti-PD-1 Drug Keytruda Phase II Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:30PM CST
Merck's (MRK) anti-PD-1 therapy, Keytruda, met the primary endpoint of progression free survival as compared to chemotherapy in a phase II study (KEYNOTE-002).
AGN: 213.14 (-0.23), MRK: 59.51 (-0.38), ABBV: 65.57 (-0.48), BMY: 58.57 (-0.13)


Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
DRTX: 24.16 (+0.41), AGN: 213.14 (-0.23), ACT: 268.17 (-1.43), VRX: 142.05 (+0.11), MRK: 59.51 (-0.38), VRX.TO: 161.13 (+0.71)

Merck PD-1 inhibitor extends PFS in melanoma
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 2:59PM CST

MRK: 59.51 (-0.38)

Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 108.29 (-0.54), GILD: 102.17 (-1.54), GERN: 3.17 (unch), MRK: 59.51 (-0.38), AZN: 75.37 (+1.39), PFE: 30.35 (-0.24), INCY: 71.40 (+1.76), BMY: 58.57 (-0.13), CTIC: 2.23 (-0.05), NVS: 95.70 (+0.12)

Merck (MRK) Breaks Through Resistance at $59.49
Comtex SmarTrend(R) - Mon Nov 17, 2:47PM CST
Merck (NYSE:MRK) has opened bullishly above the pivot of $59.13 today and has reached the first level of resistance at $59.49. Should the shares continue to rise, the resistance pivots of $59.91 and $60.69 will be of interest.
MRK: 59.51 (-0.38)

Will Merck (MRK) Stock Be Helped Today by Zetia Study?
at The Street - Mon Nov 17, 1:53PM CST
Shares of Merck (MRK) are up after the embattled drug Zetia proved effective at reducing the risk of heart attacks, strokes and other heart problems in a large, long-awaited trial.
MRK: 59.51 (-0.38)

Nopras Technologies Inc. Appoints Director Of Business Development - East Coast Operations
PR Newswire - Mon Nov 17, 1:32PM CST
Nopras Technologies (www.nopras-tech.com) has announced the appointment of Stewart B. Rosenberg to the position of Director, Business Development - East Coast Operations. Mr. Rosenberg joins Nopras from Bio-Investigations Ltd., a specialized global venture capital and new business development consultancy he founded 27 years ago, focused in the fields of human, veterinary, and agricultural health care. With undergraduate and graduate degrees in biology, biochemistry, and business from The University of Connecticut, the University of Pennsylvania, and Wharton, Mr. Rosenberg's corporate career began at Centocor (Malvern, PA), now a division of Johnson & Johnson, where he managed the In Vivo Business Unit, and at EMDS (Gibbstown, NJ), then the U.S. subsidiary of E. Merck (Darmstadt, Germany), where he managed Technology / New Ventures. Rosenberg will be geographically located for Nopras on the Eastern U.S. Coast, to particularly address the needs of biotechnology and biopharmaceutical companies heavily focused along the Boston-Washington Corridor. The position carries global responsibility.
JNJ: 108.29 (-0.54), MRK: 59.51 (-0.38)

Merck Drug Works: Vytorin Study Proves Successful
at Investor's Business Daily - Mon Nov 17, 12:35PM CST
Merck (MRK) cholesterol drug Vytorin, an ezetimibe-simvastatin combo, successfully cuts the risk of heart attacks and strokes in high-risk patients more than simvastatin alone, said the drugmaker in its nearly decade-long, 18,144-patient study. "In...
PFE: 30.35 (-0.24), MRK: 59.51 (-0.38), AMGN: 162.78 (+0.54), REGN: 416.85 (+3.63)

Vytorin successful in lowering cardiovascular events versus statin alone
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 12:02PM CST

MRK: 59.51 (-0.38)


Study lifts cloud over heart drugs Zetia, Vytorin
By MARILYNN MARCHIONE - AP - Mon Nov 17, 11:01AM CST
CHICAGO (AP) — A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. The study found that these pills modestly lower the risk of heart attacks and other problems in people at high risk for them — evidence that's been missing for more than a decade as the drugs racked up billions in sales.
MRK: 59.51 (-0.38)

Cramer: Pfizer Deal With Merck Leaves AstraZeneca In the Cold
at The Street - Mon Nov 17, 10:47AM CST
TheStreet's Jim Cramer says Pfizer's decision to buy Merck's cancer treatment business likely means an acquisition of AstraZeneca is off the table.
SHPG: 208.67 (-1.33), PFE: 30.35 (-0.24), MRK: 59.51 (-0.38), AZN: 75.37 (+1.39), ABBV: 65.57 (-0.48)

VYTORIN(R) (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Business Wire - Mon Nov 17, 10:45AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the investigational IMPROVE-IT study met its primary and all secondary composite efficacy endpoints. In IMPROVE-IT, patients taking the LDL-cholesterol-lowering medicine VYTORIN(R) (ezetimibe/simvastatin) - which combines simvastatin with the non-statin ZETIA(R) (ezetimibe) -- experienced significantly fewer major cardiovascular events (as measured by a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, re-hospitalization for unstable angina or coronary revascularization occurring at least 30 days after randomization) than patients treated with simvastatin alone. The results from this 18,144-patient study of high-risk patients presenting with acute coronary syndromes were presented today during the late-breaking clinical trials session at the American Heart Association 2014 Scientific Sessions.
MRK: 59.51 (-0.38)

Tracking Seth Klarman's Baupost Group Holdings - Q3 2014 Update
John Vincent - at Seeking Alpha - Mon Nov 17, 9:14AM CST

OCN: 21.25 (+0.20), KOS: 9.42 (+0.03), KIN: 9.04 (+0.13), VSAT: 65.65 (+0.11), RFMD: 13.69 (-0.06), EBAY: 54.99 (-0.39), TQNT: 22.85 (-0.08), IDIX: 24.50 (+0.05), SEMI: 16.57 (-0.09), VRTV: 50.68 (+2.29), THRX: 13.62 (+0.27), TBPH: 16.49 (+0.03), IMOS: 20.72 (-0.89), ELOS: 9.92 (-0.01), MU: 32.69 (-0.18), AR: 52.91 (+0.76), NCQ: 0.70 (+0.01), PBF: 28.33 (+0.67), LNG: 72.72 (+0.96), ATRA: 26.63 (+0.28), KERX: 15.26 (-0.28), NG: 2.94 (-0.09), AOI: 1.89 (-0.01), FWP: 21.40 (+0.26), BYD: 11.69 (-0.05), ALDW: 17.63 (+0.07), SUNE: 21.28 (-0.20), MRK: 59.51 (-0.38), AVEO: 0.99 (+0.04), AIG: 54.03 (+0.14)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Apani Adds Kelsun Assets to Its Natural Fiber Platform

Updated Category News Views 162

A materials deal with more chemistry than chest-thumping Seaweed and cotton have landed under one roof, which is a lot more interesting than another apparel brand slapping a green label on ordinary fabric. Apani said November 17 it acquired the assets of Keel Labs, bringing Keel's seaweed-based Kelsun fiber alongside Apani's enhanced cotton-cellulose filament technology....

Continue Reading
Snowrise Targets the Blind Spots in CPG Sales Data

Updated Category News Views 35

A sales total can look healthy while the floorboards are quietly rotting underneath it. That is the uncomfortable CPG problem Snowrise is aiming at: brands know what moved last quarter, but often cannot identify which stores, channels, communities, or promotions actually created the result. Plenty of management teams still steer by topline revenue, net distribution gains,...

Continue Reading
illumine Targets Childcare Chain Control and Risk Gaps

Updated Category News Views 10

Expansion Gets Messy Before It Gets Impressive Childcare operators do not usually stumble because they forgot how to care for children; they stumble because the back office fractures as the network grows. One center handles fees one way, another lets enrollment leads work a different funnel, and headquarters discovers too late that its reports are arguing with each other....

Continue Reading
Vuzix Bets on Lightweight Color Glasses for OEM Partners

Updated Category News Views 72

Forty grams is where this story gets interesting, because faces are ruthless product testers. People will tolerate plenty of clever technology right up until it pinches, looks goofy, leaks light, or makes them feel like they are wearing a science project. Vuzix is trying to clear that hurdle with Ultralite Color, a full-color AI eyewear reference platform built for OEM...

Continue Reading
Red Cat Stock Drama: Revenue Targets and Legal Waves

Updated Category News Views 183

Red Cat's Revenue Predictions Crash and Burn Sitting there on August 6, 2026, Red Cat Holdings had everyone believing they were on a fast track to hitting a hefty revenue target: $150–$180 million for FY2026. CEO Jeffrey Thompson didn't mince words, boasting confidence like a captain before a storm. Fast forward three months, and they're waving the white flag, tossing...

Continue Reading
Mantle's Japan Listing Puts $MNT Through a Real Test

Updated Category News Views 117

Japan's crypto gatekeepers just handed Mantle a key, not a crown. The November 18 listing of $MNT on GMO Coin is a meaningful operational win because getting onto a Japanese centralized exchange is not the usual loose-change exercise seen in friendlier jurisdictions. Mantle cleared a review process involving GMO Coin and the Japan Virtual and Crypto Assets Exchange...

Continue Reading
Markel Elevates War Risk Expertise in London Market

Updated Category News Views 73

A Specialty Desk Gets Its Own Weather Vane War and political violence underwriting is not a corner of insurance where a fancy title change can be shrugged off. The ground shifts under the policyholder, the broker and the carrier without much warning, and a bad call can sit on a book for years. Markel Insurance has named Chloe Gordge Director of War and Political Violence...

Continue Reading
Legato Frames Put Tiny AI to a Real-World Hearing Test

Updated Category News Views 231

A hearing aid that never enters the ear is a deceptively brutal product challenge. It has to hear speech through a mess of restaurant clatter, traffic, wind and ordinary human commotion; it has to run all day; and, crucially, it cannot look like a medical concession somebody reluctantly straps on. Legato Frames are aiming right at that knot, with femtoAI providing the...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 194

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
ETCO Targets the Unflashy Weak Link in Battery Storage

Updated Category News Views 16

A battery cabinet can look impressive right up until one lousy connection becomes the problem nobody budgeted for. ETCO Incorporated’s new lineup of standard and custom connectors and terminals goes after that unglamorous part of battery energy storage systems: the physical handoff points carrying power, grounding equipment, and tying auxiliary components together. It...

Continue Reading

Top 5 Most Recently Viewed Articles

Exploring the Future of Generative AI Chipset Market Growth

Updated Category News Views 252

Generative AI Chipset Market Size Analysis The Generative AI Chipset Market is experiencing remarkable growth as the demand for high-performance AI hardware accelerates across various industries. Currently valued at approximately USD 37.29 billion in 2023, the market is anticipated to reach an impressive USD 454.50 billion by 2032, representing a staggering compound...

Continue Reading
CrateDB Welcomes Robert Ekstrom as New Chief Executive Officer

Updated Category News Views 297

CrateDB Welcomes Robert Ekstrom as New Chief Executive Officer CrateDB, the groundbreaking real-time database solution designed for analytics, search, and AI applications, has announced the exciting appointment of Robert Ekstrom as the new Chief Executive Officer. His leadership is viewed as a pivotal moment for the company, propelling its growth strategies and...

Continue Reading
Novartis AGM Highlights: Board Changes and Dividend Increase

Updated Category News Views 463

Key Outcomes from Novartis' Annual General Meeting Today, Novartis held its Annual General Meeting (AGM) where shareholders gathered to discuss and approve various resolutions proposed by the Board of Directors. It was an important day for the company, as a strong turnout highlighted investor engagement and confidence. Dividend Increase for 2024 This year marks a...

Continue Reading
Understanding Alliance Witan PLC's Net Asset Valuation Insights

Updated Category News Views 116

Understanding Alliance Witan PLC's Financial Standing Alliance Witan PLC stands out in the investment landscape, offering its shareholders a detailed look at their Net Asset Value (NAV). As of the latest reporting date, the financial metrics reveal significant information pertaining to the company's performance and shareholder value. Net Asset Value Calculation At the...

Continue Reading
Remembering Jimmy Carter: A Legacy of Service and Humanity

Updated Category News Views 375

Remembering Jimmy Carter: A Legacy of Service and Humanity Habitat for Humanity joins millions around the globe in reflecting on the remarkable life of former U.S. President Jimmy Carter. He is widely recognized not only as a political leader but also as a formidable advocate for affordable housing. A Champion for Affordable Housing Throughout his life, President Carter...

Continue Reading